Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1993-08-04
1997-01-14
Chan, Christina Y.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 11, 530300, 530307, 530324, A61K 3800, A61K 3802, A61K 3830, C07K 500
Patent
active
055939627
ABSTRACT:
The invention provides fibrillated calcitonin for use in treating calcium deficiency diseases.
REFERENCES:
patent: 4690952 (1987-09-01), Kagatani et al.
Arvinte, et al "Comparative Study of Human and Salmon Calcitonin Secondary Structure in Solutions With Low Dielectric Constants" J. Biol. Chem. 268(9):6408-6414 (1993).
Arvinte, et al. "The Structure and Mechanism of Formation of Human Calcitonin Fibrils" J. Biol. Chem 268(9):6414-6422 (1993).
Sieber, et al. "Menschliches Calcitonin. Die Synthese Von Calcitonin M.sup.2 " Helvetica Chimica Acta 53:2135-2150(1970)-includes English Summary.
European Search Report dated 14 Jul. 1993.
Sieber P, et al. "Menschliches Calcitonin VT.sup.1). Die Synthese von Calcitonin M.sup.2)" Helvetica Chimica Acta. 53(8)2135-2150 (1970) (Abstract).
Levy, et al. "Formation of Neutralizing Antibodies During Intranasal Synthetic Salmon Calcitonin Treatment of Pagets Disease", J. Clin. Endocrinol. Metab. 67:541-545 (1988).
Grauer, et al. "In Vitro Detection of Neutralizing Antibodies After Treatment of Pagets Disease of Bone With Nasal Salmon Calcitonin" J. Bone Min Res. 5(4):387-391 (1990).
Dietrich, et al. "Synthetic Human Calcitonin: Analysis of Antibodies Obtained from Various Animal Species and Determination of Immunoreactive Hormone in Human Sera" Acta Endocrinol. 80:465-485 (1975).
Dietrich, et al "Formation of Antibodies to Synthetic Human Calcitonin During Treatment of Pagets Disease" Acta Endocrinol. 92:468-476 (1979).
Moran, et al. "Calcitonin and Calcium Inophores: Cyclic AMP responses in cells of a human lymphoid line" Proc. Natl. Acad. Sci 75(8)3984-8 (1978).
Aloia, et al. "Treatment of Osteoporosis With Calcitonin, With and Without Growth Hormone" Metabolism 34(2):124-129 (1985).
Gruber, et al "Long Term Calcitonin Therapy in Postmenopausal Osteoporosis" Metabolism 33(4):295-303 (1984).
Rojanasathit, et al. "Pagets Bone Disease: Response To Human Calcitonin In Patients Resistant To Salmon Calcitonin" Lancet 2:1412-1415 (1974).
Singer et al, "An Evaluation of Antibodies and Clinical Resistance to Salmon Calcitonin" J. Clin Invest 51(3):2331-2338 (1972).
Herbert, et al. "Coated Charcoal Immunoassay of Insulin" J Clin Endocrinol Metals 25:1375-1384 (1965).
Roos et al. "Evaluation of the in Vivo and in Vitro Calcium Regulating Actions of Noncalcitonin Peptides Produced via Calcitonin Gene Expression" Endocrinology 118(1):46-51 (1986).
Woodhouse, et al "Development and Significance of Antibodies to Salmon Calcitonin in Patients With Pagets Disease on Long Term Treatment" Br Med J 2:927-929 (1977).
Raue, et al. "Action of Calcitonin Gene Related Peptide at the Calcitonin Receptor of the T47D Cell Line" Horm Metabol Res 19:563-4 (1987).
Nagant, et al "New Modes of Administration of Salmon Calcitonin in Pagets Disease" Clin Orthop Rel Res 217:56-71 (1987).
Findlay, et al "Calcitonin and 1,25-dihydroxyvitamin D.sub.3 receptors in Human Breast Cancer Cell Lines" Cancer Res 40:4764-4767 (1980).
Pontiroli, et al "Intranasal Calcitonin and Plasma Calcium Concentrations in Normal Subjects" Br Med J 290:1390-1391 (1985).
Singer, et al "Salmon Calcitonin Therapy for Pagets Disease of bone" Arthritis Rheun 23:1148-1153(1980).
Altman, et al "Synthetic Human Calcitonin in Refractory Paget's Disease of Bone" Arch Intern Med 147:1305-1308 (1987).
Wohlwend, et al. "Calcitonin and Calcitonin Gene-Related Peptide Interact with the Same Receptor in Cultured LLC-PK.sub.1 Kidney Cells" Biochem Biophys Res Commun 131(2):537-542 (1985).
Lamp, et al "Calcitonin Induction of a Persistant Activated State of Adenylate Cyclase in Human Breast Cancer Cells" (T47D) J. Biol Chem 256(23):12269-74 (1981).
DeRose, et al "Response on Pagets Disease to Porcine and Salmon Calcitonin" Am J Med 56:858-866 (1974).
Haddad, et al. "Calcitonin Resistance Clinical and Immunologic Studies in Subjects With Pagets Disease of Bone Treated With Porcine and Salmon Calcitonin" J Clin Invest 51:3133-40 (1972).
Armbruster, F. P. et al "C-AMP Protein Bindungs Assay: Proteinabhangigkeit der cAMP-Bindung" Aerztl Lab 32:115-120 (1986).
Diem, et al. Documenta Geigy Wissenschaftliche Tabellen, ed 7 p. 146 (1968).
Mazzuoli, et al. "Effects of Salmon Calcitonin in Postmenopausal Osteoporosis: A Controlled Double-Blind Clinical Study" Calcif Tissue Int 38:3-8 (1986).
Buclin, et al. "The Effect of Rectal and Nasal Administration of Salmon Calcitonin in Normal Subjects" Calcif Tissue Int 41:252-258 (1987).
Kurose, et al "Intranasal Absorption of Salmon Calcitonin" Calcif Tissue Int 41:249-251 (1987).
Reginster, et al "Salmon Calcitonin Nasal Spray in Pagets Disease of Bone: Primary Results in Five Patients" Calcif Tissue Int 37:577-580 (1985).
LoCascio, et al "Response of Paget's Disease to Human Calcitonin in Patients Resistant to Porcine Calcitonin" J Endrocrinol Invest 7:85-88 (1984).
Nagant de Deuxchaisnes "Effect of a Nasal Spray of Salmon Calcitonin in Normal Subjects and Patients with Pagets Disease" Calatonin 329-343 (1984).
Singer, et al. "Pagets Bone Disease: Etiologic and Therapeutic Aspects" Bone and Mineral Research vol. 2:394 (1983).
Arvinte Tudor
Cudd Amelia
Phillips Judith
Chan Christina Y.
Ciba-Geigy Corporation
Davenport A. M.
Fishman Irving M.
Kaiser Karen G.
LandOfFree
Fibrillated calcitonin pharmaceutical compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fibrillated calcitonin pharmaceutical compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fibrillated calcitonin pharmaceutical compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1388173